



(11) **EP 1 790 339 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 158(3) EPC

- (15) Correction information:
Corrected version no 1 (W1 A1)
Bibliography INID code(s) 72, 86
- (48) Corrigendum issued on:
09.07.2008 Bulletin 2008/28
- (43) Date of publication:
30.05.2007 Bulletin 2007/22
- (21) Application number: **06780884.0**
- (22) Date of filing: **07.07.2006**
- (51) Int Cl.:
A61K 31/232 (2006.01) A61K 45/00 (2006.01)
A61P 9/10 (2006.01) A61P 43/00 (2006.01)
- (86) International application number:
PCT/JP2006/313609
- (87) International publication number:
WO 2007/007686 (18.01.2007 Gazette 2007/03)

- (84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
- (30) Priority: **08.07.2005 JP 2005200503**
- (71) Applicant: **MOCHIDA PHARMACEUTICAL CO., LTD.**
Shinjuku-ku
Tokyo 160-8515 (JP)
- (72) Inventors:
• **YOKOYAMA, Mitsuhiro**
Kobe-shi, Hyogo 651-1112 (JP)
• **ORIGASA, Hideki**
Toyama-shi, Toyama 930-0138 (JP)
• **MATSUZAKI, Masunori**
Ube-shi, Yamaguchi 755-0152 (JP)
• **MATSUZAWA, Yuji**
Takarazuka-shi, Hyogo 665-0804 (JP)
• **SAITO, Yasushi**
Chiba-shi, Chiba 260-0853 (JP)
• **ISHIKAWA, Yuichi**
Kobe-shi, Hyogo 651-2276 (JP)
- **OIKAWA, Shinichi**
Tokyo 113-0022 (JP)
 - **SASAKI, Jun**
Fukuoka-shi, Fukuoka 814-0015 (JP)
 - **HISHIDA, Hitoshi**
Nagoya-shi, Aichi 451-0042 (JP)
 - **ITAKURA, Hiroshige**
Tokyo 108-0074 (JP)
 - **KITA, Toru**
Kyoto-shi, Kyoto 606-0941 (JP)
 - **KITABATAKE, Akira**
Nara-shi, Nara 631-0023 (JP)
 - **NAKAYA, Noriaki**
Tokyo 164-0003 (JP)
 - **SAKATA, Toshiie**
Fukuoka-shi, Fukuoka 810-0017 (JP)
 - **SHIMADA, Kazuyuki**
Utsunomiya-shi, Tochigi 320-0851 (JP)
 - **SHIRATO, Kunio**
Sendai-shi, Miyagi 980-0871 (JP)
- (74) Representative: **Grünecker, Kinkeldey, Stockmair & Schwanhäusser**
Anwaltssozietät
Leopoldstrasse 4
80802 München (DE)

(54) **COMPOSITION FOR PREVENTION OF OCCURRENCE OF CARDIOVASCULAR EVENT**

(57) Provided is composition, containing ethyl icosapentate as its effective component, which is useful in preventing onset and/or recurrence of cardiovascular events; especially expected is preventive effect of onset and/or recurrence of those which occur or recur irrespec-

tive of the treatment with HMG-CoA RI in hyperlipidemia patients and those which occur after the unstable period after cardiovascular angioplasty is over.

EP 1 790 339 A8